Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company, announced updated interim data from their ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin $(GRN)$ mutations. The company reported that PBFT02 continued to show robust and durable elevation in cerebrospinal fluid progranulin levels and improvement in plasma neurofilament light chain levels, a biomarker for disease progression. Passage Bio plans to amend the trial protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in the disease progression. The company remains on track to seek regulatory feedback on the FTD-GRN pivotal trial design in the first half of 2026. Results from the study have already been presented, and further updates are anticipated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.